Sven Rohmann, MD, PhD, Chief Business Officer

Dr. Dr. Sven Rohmann has a scientific, academic background in clinical medicine and basic research.

He spent 10 years at Merck Serono, which provided him with a strong foothold in the pharmaceutical industry. His career exposed him to pre-clinical, clinical development as well as marketing, business and corporate development. During his tenure at Merck he was involved in the successful licensing of Erbitux from ImClone and the establishment of Merck Oncology.

Sven joined Burrill & Company in 2010. Prior to joining Burrill & Company, he worked as Venture Capital Fund Manager for Novartis Pharma AG, and as Managing Partner at Nextech Venture, both Switzerland. In addition, he served as CEO of two European biotech start-ups and gained board experience at three SME’s in Germany.

Sven´s unique blend of scientific, pharma/biotech and venture knowledge, an extensive network of contacts among health care providers as well as academic and government research administrators, a thorough knowledge of European research and regulatory policies, and a significant experience in global as well as European partnering significantly extends the investment reach of Burrill & Company towards Europe.

Sven received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University, Rotterdam, Netherlands.